MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4209
-0.0191
-4.34%
Closed 16:00 04/01 EDT
OPEN
0.4300
PREV CLOSE
0.4400
HIGH
0.4400
LOW
0.3900
VOLUME
154.42K
TURNOVER
--
52 WEEK HIGH
1.486
52 WEEK LOW
0.2943
MARKET CAP
20.19M
P/E (TTM)
-0.6982
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VTGN stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.

EPS

VTGN News

More
  • VistaGen Therapeutics inks $10M stock purchase agreement; shares up 13% premarket
  • seekingalpha · 03/25 18:26
  • VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
  • PR Newswire · 03/25 14:00
  • VistaGen up 15% premarket on positive PH10 data
  • Seeking Alpha - Article · 02/20 13:53
  • VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
  • PR Newswire · 02/20 13:30

Industry

Pharmaceuticals
-2.46%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About VTGN

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
More

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.